Cytokinetics Director Edward M. Kaye Receives 191-Share Award

What Happened

• Edward M. Kaye, M.D., a director of Cytokinetics, received an award of 191 shares of CYTK common stock on 2026-04-15. The grant is reported at a per-share value of $65.37, for a total reported value of $12,486. This transaction is coded as an award/grant (A) and the shares are fully vested upon issuance.

Key Details

• Transaction date: 2026-04-15
• Transaction type: Award/Grant (code A) under the Director Equity in Lieu of Cash Retainer Program
• Shares granted: 191 at $65.37 each; total reported value $12,486
• Vesting/status: Shares are fully vested (per footnote)
• Shares owned after transaction: Not disclosed in the provided filing data
• Filing timeliness: Reported and filed on 2026-04-15 (timely)

Context

• This was a compensation grant to a director in lieu of a cash retainer, not an open-market purchase or sale. Such awards are routine director compensation and, while they increase insider ownership, they do not necessarily signal a personal net cash investment or change in sentiment.